Presentation is loading. Please wait.

Presentation is loading. Please wait.

Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes.

Similar presentations


Presentation on theme: "Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes."— Presentation transcript:

1 Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes

2

3

4 Case Study

5

6

7

8

9

10

11 Relapsed Multiple Myeloma What Do You Do With Patients After RVD?

12

13 Cytogenetics A Parameter That, in Isolation, Should Be Used With Caution

14

15

16

17

18

19 Should Consolidation Therapy Be Considered After HDT/ASCT? Yes!

20 Relapsed and/or Refractory MM When to Use the Next Generation of the Existing Class of Agents and When to Use a New Class of Agents

21 Relapsed and/or Refractory MM Novel mAbs

22

23 Relapsed and/or Refractory MM Novel Proteasome Inhibitors

24

25 Relapsed and/or Refractory MM Pomalidomide, a Third-Generation IMiD

26

27 Relapsed and/or Refractory MM Small Molecule Inhibitors

28

29

30

31 Thank you for participating in this activity.


Download ppt "Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes."

Similar presentations


Ads by Google